HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

9th Edition of International Conference on

Neurology and Neurological Disorders

June 20-22, 2024 | Paris, France

Neurology 2023

Ken Ware

Speaker at Neurology and Neurological Disorders 2023 - Ken Ware
NeuroPhysics Therapy Institute, Australia
Title : Neuro Physics Therapy (NPT) shows to be a highly effective psychophysical treatment for its patients enduring advanced Facio Scapulohumeral Muscular Dystrophy (FSH, FSHD) symptoms, with significant sustainable generation of lost or highly compromised functions being realized in very small time scales

Abstract:

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most frequent hereditary muscle disorders. 

It is said to be a ‘genetic’ muscle disorder in which the muscles of the face, shoulder blades, and upper arms are among the most affected. This presentation will include the outcomes of four FSHD patients (case studies) who all presented suffering from varying degrees of advanced FSHD symptoms. The length of time since these patients were diagnosed with FSHD varied from 30 years pre-NPT treatment to 4 years pre-NPT treatment, with the most phenomenal sustainable generation of lost or highly compromised functions being realised in the patients having the longest-term diagnosis pre NeuroPhysics Therapy treatment. All patients received NPT treatment over four consecutive days involving 2-hour treatments each day.

This presentation will also include published data and video testimonials. The profound outcomes for each of these patients excites obvious questions and levels of inquiry. Each patients’ symptoms progressively advanced since their diagnosis despite pharmacological intervention. ‘There is a consensus that FSHD is caused by the aberrant production of the double homeobox protein 4 (DUX4) transcription factor in skeletal muscle. DUX4 is normally expressed during early embryonic development, and is then effectively silenced in all tissues except the testis and thymus. Its reactivation in skeletal muscle disrupts numerous signaling pathways that mostly converge on cell death’ Kenji Rowel Q. Lim, et al;  https://doi.org/10.3390/ijms21030729 If this is the case, than how is possible for these patients to generate such profound outcomes and in such very small time frames? This will be discussed during this presentation.

Keywords: Facioscapulohumeral muscular dystrophy (FSHD), NeuroPhysics Therapy Treatment, Genetic Disorders, Psychophysical Treatment.

Biography:

Ken Ware was founder of Neurotricional Sciences Pty Ltd and NeuroPhysics Therapy and Research and he had been in private practice for almost 30 years, while doing independent and collaborative research. He also presented unique research at 10 major International Science Conferences including neuroscience, Physics, Psychology and Life Sciences, which covers a very broad scientific audience. He is Former Mr. Universe 1994, National powerlifting and Bodybuilding champion and record holder. He had published relative publications in ‘Frontiers in Clinical Physiology’ - ‘World Journal of Neuroscience’ – ‘World Journal of Cardiovascular diseases’. He is recipient of Her Majesty, Queen Elizabeth’s’ ‘Australian Sports Medal’ - in 2000, in recognition for personal contributions to the development of the Australian Sporting Culture.

Watsapp